Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Jennifer Guerriero, PhD


No Ratings Available - Why Not?

Jennifer Guerriero, PhD


  • Assistant Professor, Harvard Medical School
  • Lead Investigator, Brigham and Women’s Hospital
  • Director, Breast Tumor Immunology Laboratory (BTIL), Women’s Cancer Program, Dana-Farber Cancer Institute


Clinical Interests

  • Breast cancer
  • Immuno-oncology

Contact Information

  • Office Phone Number617-582-9759


Dr. Guerriero has a PhD in Molecular and Cellular Biology and Immunology and Pathology from Stony Brook University where she trained under Dr. Wei-Xing Zong and completed her thesis entitled, “A study of cell death pathways and innate immunity in cancer chemotherapy”. Dr. Guerriero completed her postdoctoral training in the laboratory of Dr. Anthony Letai at Dana-Farber Cancer Institute where she investigated the role of tumor macrophages in breast cancer and identified novel mechanisms to target pro-tumor macrophages to an anti-tumor phenotype to induce tumor regression. Dr. Guerriero transitioned to a faculty position as an Instructor in Medicine at Harvard Medical School and joined Dr. Elizabeth Mittendorf's laboratory as the Director of the Breast Tumor Immunology Laboratory in the Susan F. Smith Women’s Cancer Program at Dana-Farber Cancer Institute. In October 2020, Dr. Guerriero launched her independent laboratory at Brigham and Women's Hospital and continues to serve as the Director of the Breast Tumor Immunology Laboratory.


The Guerriero Lab aims to design clinically effective strategies to promote T-cell activation and weaken the immune-suppressive tumor microenvironment to improve immunotherapy response rates in breast cancer patients. They seek to identify tumor-promoting tumor macrophages in breast tumors before and after therapy, elucidate their molecular and metabolic regulation that promotes immune suppression and therapy-resistance and determine how tumor macrophage phenotype, metabolism and function can be modulated for anti-tumor responses. The overall goal is to accelerate breast cancer immunotherapy by harnessing tumor associated macrophages.


Dana-Farber Cancer Institute (BTIL)
450 Brookline Ave
Smith 928
Boston, MA 02215
Get Directions

Brigham and Women’s Hospital (Guerriero Lab)
20 Shattuck Street
Thorn 407
Boston, MA 02115
Get Directions